BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/29/2016 5:11:00 PM | Browse: 1319 | Download: 2097
 |
Received |
|
2015-07-02 09:23 |
 |
Peer-Review Started |
|
2015-07-06 08:31 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2015-07-31 14:56 |
 |
Revised |
|
2015-08-15 04:28 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2015-11-09 10:51 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2015-11-25 16:30 |
 |
Articles in Press |
|
2015-11-25 16:30 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-01-16 19:35 |
 |
Publish the Manuscript Online |
|
2016-01-29 17:09 |
| ISSN |
2218-6190 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Dermatology |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Khaled Benkali, François Rony, Michael Graeber, Jean Jacovella, Jean-Paul Chappuis, Marie-Helene Peirone, Michel Poncet, Stéphane Delage, Ronan Bouer and Nathalie Wagner |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Khaled Benkali PhD, Galderma R and D, Les Templiers, 2400, route des Colles, 06410 Biot,
France. khaled.behkali@galderma.com
|
| Key Words |
Ivermectin; Pharmacokinetic maximal usage trial; Metabolites; Plasma and rosacea |
| Core Tip |
Papulopustular rosacea (PPR) is a chronic skin disease affecting patients face, with a dramatic impact on social and professional interactions. Ivermectin 1% cream is a new effective and safe treatment for PPR recently approved in many countries. This article presents the clinical pharmacokinetics (PK) assessments conducted during the drug development of Ivermectin 1% cream. Usually, for topical products, PK assessments are incomplete due to the low systemic exposure. For ivermectin cream, a comprehensive PK and metabolism program was conducted in healthy volunteers and PPR patients up to 1 year treatment. These provided valuable information to better assess ivermectin safety profile.
|
| Publish Date |
2016-01-29 17:09 |
| Citation |
Benkali K, Rony F, Graeber M, Jacovella J, Chappuis JP, Peirone MH, Poncet M, Delage S, Bouer R, Wagner N. Clinical pharmacokinetics profile of ivermectin 1% cream after dermal applications on the face. World J Dermatol 2016; 5(1): 57-64 |
| URL |
http://www.wjgnet.com/2218-6190/full/v5/i1/57.htm |
| DOI |
http://dx.doi.org/10.5314/wjd.v5.i1.57 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.